PRWeek | 2021 Will Be Known As Year Medcomms M&A Went Into Overdrive
Several large agency groups have taken on fresh private equity capital for the first time this year and many others have changed private equity ownership.
In each case, the thesis is simple: buy your way to growth and a full-service proposition.
Full-service medcomms spans everything from pre-clinical R&D strategy through medical affairs and market access work during clinical trials, and across to the marketing and creative work for brand launches (and relaunches) – and everything in between.
Within each bucket there are several niches in a sector known for being highly fragmented.
As the larger medcomms platforms scale and their valuations rise, this has corresponded to smaller agencies also experiencing a rise in valuations.
Deal structures now tend to be more attractive to sellers than in previous years, typically tying agency owners to the growth of the overall acquiring group and not solely the performance of the target company.
The days of the five-year earnout have largely disappeared and been replaced with more favourable win-win arrangements.
As bigger groups have greater firepower to acquire, sellers continue to sell.
The 10 most active medcomms acquirers have bought 19 companies so far in 2021, with many others being acquired by other medcomms agencies or non-healthcare buyers.
The trend from 2021 is that private equity-backed acquirers are accelerating the pace of M&A across Europe and the US, in particular.
Why are we experiencing heightened activity?
The pharma medcomms market is one of the most attractive sectors to operate in. It’s worth more than $10bn in 2021 and is growing 12 per cent annually, with medical affairs and publication work making up the largest budgets across the sub-sectors.
The focus on this sector compared with other industries remains high and I can’t see the spotlight moving off outsourced pharma services for years to come.
The tailwinds keeping the conveyor belt of M&A moving include:
- Fresh private equity capital in the sector.
- A continued focus on pharma and healthcare.
- Outsourcing trends within pharma increasing and staying elevated.
- The need for more complex data and analytical requirements which can only be performed by outsourced specialists.
This all drives the market forward and acts as an additional incentive for new agencies to have innovative services at the core of their business.
One major challenge for top acquirers will be retaining culture and spark, which is often a key reason agencies are so attractive to them. I’ve seen huge strides being made by acquirers to ensure culture remains in place post-acquisition.
Independent agency owners across the pharma and life science space will have a red-hot phone line as the private equity-backed platforms continue to grow through acquisition.
Managing Director James West provides his perspective in PRWeek on private equity trends in the medcomms sector.
- Sign up to receive Lincoln's perspectives
Meet Professionals with Complementary Expertise
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Managing Director | Management Board MemberFrankfurt
In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners
Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More
In Q3 2020, Lincoln International introduced Lincoln’s Latest video series. Experts from across industries, services and geographies, share perspectives on current trends, recent observations and future outlooks through this video… Read More
Surging Medical Inflation Fuels Continued Interest in Self-Funding and Cost Containment
During the past 18 months, inflation has accelerated to levels not seen since the early 1980s. The cost of energy, food and other staples has increased rapidly and is expected… Read More
Lincoln International Expands Presence to Southeast, Opening Miami and Atlanta Offices
Continued growth spurs openings in new geographies for both client coverage and talent acquisition Lincoln International announced today that it has expanded its U.S. footprint with the opening of offices… Read More
Recent Transactions in Healthcare
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Lincoln International advised EverVet Partners, a portfolio company of Tailwind Capital, on receiving a significant investment from Freeman Spogli & Co.
Lincoln International has advised All About Children on its sale to Partou, a portfolio company of Waterland Private Equity
Lincoln International advised SEKISUI CHEMICAL on the sale of SEKISUI XENOTECH to BioIVT, a portfolio company of Linden Capital Partners